Logo 1 Logo 2

Clinical Trial Details

Trial ID: L3575
Source ID: NCT03466567
Associated Drug: Semaglutide
Title: A Trial Investigating the Effect of Probenecid and Ciclosporin on the Concentrations of SNAC in Healthy Subjects
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Diabetes|Diabetes Mellitus, Type 2
Interventions: DRUG: Semaglutide|DRUG: Probenecid|DRUG: Ciclosporin
Outcome Measures: Primary: AUC0-tz,SNAC,SD, area under the SNAC plasma concentration-time curve from time 0 to time of the last quantifiable concentration after a single dose of oral semaglutide, Calculated based on plasma SNAC activity measured in blood., 0-48 hours|Cmax,SNAC,SD, maximum observed SNAC plasma concentration on the concentration-time curve after a single dose of oral semaglutide, Calculated based on plasma SNAC activity measured in blood., 0-48 hours | Secondary: AUC0-tz,E494,SD, area under the SNAC metabolite E494 plasma concentration-time curve from time 0 to time of the last quantifiable concentration after a single dose of oral semaglutide, Calculated based on plasma SNAC metabolite E494 activity measured in blood., 0-48 hours|Cmax,E494,SD, maximum observed SNAC metabolite E494 plasma concentration on the concentration-time curve after a single dose of oral semaglutide, Calculated based on plasma SNAC metabolite E494 activity measured in blood., 0-48 hours|AUC0-tz,E506,SD, area under the SNAC metabolite E506 plasma concentration-time curve from time 0 to time of the last quantifiable concentration after a single dose of oral semaglutide, Calculated based on plasma SNAC metabolite E506 activity measured in blood., 0-48 hours|Cmax,E506,SD, maximum observed SNAC metabolite E506 plasma concentration on the concentration-time curve after a single dose of oral semaglutide, Calculated based on plasma SNAC metabolite E506 activity measured in blood., 0-48 hours|AUC0-∞,E1245,SD, area under the SNAC metabolite E1245 plasma concentration-time curve from time 0 to infinity after a single dose of oral semaglutide, Calculated based on plasma SNAC metabolite E1245 activity measured in blood., 0-48 hours|Cmax,E1245,SD, maximum observed SNAC metabolite E1245 plasma concentration on the concentration-time curve after a single dose of oral semaglutide, Calculated based on plasma SNAC metabolite E1245 activity measured in blood., 0-48 hours|AUC0-∞,E1246,SD, area under the SNAC metabolite E1246 plasma concentration-time curve from time 0 to infinity after a single dose of oral semaglutide, Calculated based on plasma SNAC metabolite E1246 activity measured in blood., 0-48 hours|Cmax,E1246,SD, maximum observed SNAC metabolite E1246 plasma concentration on the concentration-time curve after a single dose of oral semaglutide, Calculated based on plasma SNAC metabolite E1246 activity measured in blood., 0-48 hours|AUC0-∞,E1247,SD, area under the SNAC metabolite E1247 plasma concentration-time curve from time 0 to infinity after a single dose of oral semaglutide, Calculated based on plasma SNAC metabolite E1247 activity measured in blood., 0-48 hours|Cmax,E1247,SD, maximum observed SNAC metabolite E1247 plasma concentration on the concentration-time curve after a single dose of oral semaglutide, Calculated based on plasma SNAC metabolite E1247 activity measured in blood., 0-48 hours
Sponsor/Collaborators: Sponsor: Novo Nordisk A/S
Gender: ALL
Age: ADULT
Phases: PHASE1
Enrollment: 21
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2018-03-15
Completion Date: 2018-07-10
Results First Posted:
Last Update Posted: 2019-06-19
Locations: Novo Nordisk Investigational Site, Berlin, 14050, Germany
URL: https://clinicaltrials.gov/show/NCT03466567

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress